We need to make clear that monopoly grants come with responsibility and accountability, and that competition is more important to the public than a blank check for innovation we cannot afford. Read More
CalPERS said it spent nearly $40 million for Sovaldi on plans run by Blue Shield of California, Kaiser Permanente and CVS Health. Read More
Sophisticated drugs are opening the door, scientists say, to an era of "precision medicine." They're also ushering in an age of astronomical prices. Read More
Originally published on AmericanPharmacyNews.com. Read More
Are Skyrocketing Drug Prices Really Needed for Innovation? Amgen’s… Read More
Sky-high drug prices have been causing their fair share of consternation among payers lately, and industry watchers have suspected for a while now that Vertex ($VRTX) will stir the pot when its new cystic fibrosis combo--expected to win FDA approval later this year--hits the market. But just how much will payers need to shell out for the new med over time? Prime Therapeutics has some ideas. Read More
Drug retail giant CVS Health Corp. is girding to do battle with pharmaceutical companies over a coming class of cholesterol drugs that CVS says could cost the nation’s health-care system $150 billion a year. Read More
Ever since Obamacare took effect, Republicans have warned of mission creep: that a law bringing more government regulation to health care would eventually morph into single-payer. Read More
A national group of more than 140,000 physicians on Tuesday joined a coalition dedicated to reversing the growing trend of high-cost specialty drugs, which are being blamed for straining the finances of patients, insurance plans and public health coverage programs. Read More
With patients facing more exposure to the cost of revolutionary new medications, the budget President Barack Obama released Monday reopened a debate on whether government should use its buying power to squeeze the pharmaceutical industry for lower prices. Read More
Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Last year, Gilead’s Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September. Read More
The Obama administration’s fiscal 2016 budget request calls for allowing the government to negotiate the price of prescription drugs and giving regulators new funding to fight Ebola. Read More